Evidence map›Paper›PMID 41383982›Full record

ReviewOncology letters2026

Role of HOXA transcript antisense RNA myeloid-specific 1 in cancer (Review).

Yipei Jing, Xiaoqi Li, Ye Guo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yipei JingDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, P.R. China.
Xiaoqi LiDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, P.R. China.
Ye GuoDepartment of Clinical Laboratory, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A newly recognized class of master regulators known as long non-coding RNAs (lncRNAs) has emerged as key modulators of cancer. Among them, HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) was initially identified in acute promyelocytic leukemia, where it resides within the HOXA gene cluster. The involvement of HOTAIRM1 has been indicated in the pathogenesis of multiple cancer types, including glioma, acute myeloid leukemia and osteosarcoma, has been well documented. HOTAIRM1 controls the growth, invasion and migration of tumors through different mechanisms and it is associated with the clinicopathological characteristics of patients with tumors. The present review describes the expression, function and molecular mechanism of HOTAIRM1 in different types of cancer and discusses the future obstacles in diagnosing and treating malignant tumors.

Indexed as

cancerfunctionHOTAIRM1lncRNAregulator

Identifiers

PMID41383982
PMCPMC12690531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.